Community-acquired pneumonia (CAP), one of the common infectious diseases, exhibits increasing morbidity and mortality with age, posing significant clinical challenges. Although Chinese patent medicines (CPMs) demonstrate efficacy in adult CAP treatment, high-quality evidence-based guidelines have been lacking. To address this gap, we organized a multidisciplinary expert panel to develop the Guideline on Treating Community-acquired Pneumonia with Chinese Patent Medicines, adhering to the principles of evidence-based, consensus-supplemented, and experience-referred and following standardized clinical practice guideline development procedures. Through literature review and Delphi questionnaires, six clinical questions were identified. Systematic evidence retrieval and synthesis of the best available evidence were conducted, integrating factors such as evidence quality, patient preferences, value orientations, and resource allocation. After two rounds of Delphi surveys and expert consensus meetings, the guideline was finalized and published in 2023 in Pharmacological Research. This updated edition systematically incorporates recent evidence, adds pharmacoeconomic evaluations and recommendation rationales, and presents 14 recommendations covering nine CPMs, covers 9 kinds of traditional Chinese patent medicines. The guideline has been restructured according to the first edition of reporting checklist for Chinese patent medicine guidelines (RIGHT for CPM) to enhance clinical applicability, accessibility, and operationalizability, thereby promoting the rational use of CPMs in adult CAP treatment.